Jobs / United States / Pfizer INC
Director, US TUKYSA Brand Strategy Lead
Pfizer INC · 🇺🇸 3 Locations
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 40 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 9 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Pfizer INC paid sponsored hires in similar roles1 certified filing for “Associate Director, Statistics Lead” (Statisticians) in VA: $135k–$135k, median $135k. Most were filed at wage level III (100%) — 3 lottery entries, ≈46% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Pfizer INC
The US Department of Labor certified 40 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 9 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Pfizer INC →
About the role
What You Will Achieve Pfizer Commercial Oncology is introducing the world to the next era of cancer care. With a growing portfolio of novel therapies, industry-leading R&D, and a goal of delivering eight breakthroughs by 2030 across major cancer types, we're translating cutting-edge science into market-shaping impact. Here, you'll partner with exceptional colleagues across scientific, medical, and manufacturing teams, backed by advanced digital and AI-enabled infrastructure and the authority to accelerate medicines from discovery to delivery. Guided by our values of courage, excellence, equity, and joy, you'll have the opportunity to stretch your skills and build a career that evolves with you — across teams, roles, and the Pfizer enterprise. Join us to make history — for patients, for their families, for the future. At Pfizer Oncology, our mission is to "Outdo Cancer" by developing transformative therapies that make a meaningful impact for patients. Pfizer Oncology currently boasts an industry-leading portfolio spanning breast as well as genitourinary (GU) cancers, hematology-oncology, gastrointestinal-oncology, and thoracic cancers. The US Breast Cancer Business is one of the largest businesses within Pfizer Oncology. It is anchored by a multibillion-dollar asset IBRANCE, as well as TUKYSA in metastatic breast cancer, and a robust pipeline of breast cancer innovation. TUKYSA is entering one of the most consequential windows in the brand's history with the anticipated launch of the HER2CLIMB-05 first-line maintenance (1Lm) indication in human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC, PDUFA Oct 17, 2026). HER2CLIMB-05 marks a new era for the Pfizer Breast Cancer Franchise, with TUKYSA poised as the franchise growth driver. TUKYSA is also indicated for HER2+ metastatic colorectal cancer (mCRC). Over the next years, several pivotal trial readouts are anticipated across both mBC and mCRC for TUKYSA. The Strategy & Performance Lead is a critical strategic and operational role. Operating as an individual contributor in a highly matrixed environment, the role drives US commercial strategic planning, business operations, and demand-based performance management.The ideal candidate is a strategic thinker who turns complex, ambiguous data into clear commercial direction — pairing analytical rigor and data-driven decision-making with the communication skills and influence to move senior cross-functional stakeholders toward it. US launch exposure is strongly valued. The Director, US TUKYSA Strategy & Performance Lead will report to the Sr. Director, US TUKYSA Commercial & Marketing Team Lead and be part of a mission-driven, innovative, and talented team of diverse colleagues. ROLE RESPONSIBILITIES Key responsibilities include but are not limited to: Strategic Planning • Own the strategic agenda for TUKYSA: proactively surfacing issues that need a decision early, framing the options and implications, and drive recommendations to resolution with the relevant business and functional leaders • Define the 3-year US commercial strategy across both metastatic breast cancer and metastatic colorectal cancer • Develop the competitive strategy and positioning for TUKYSA in the evolving HER2+ mBC treatment landscape • Build and advocate the case for select and targeted TUKYSA's prioritization within enterprise customer-facing resources, partnering with Account Marketing and Account Management leadership • Lead strategic assessment of mCRC opportunities and build business cases for resourcing and investment, as appropriate • Represent US Commercial in commercial development, clinical development and regulatory plans, partnering with Global Marketing and Research & Development Business Operatio